Stocks and Investing Stocks and Investing
Thu, October 11, 2018
Wed, October 10, 2018
Tue, October 9, 2018
Mon, October 8, 2018
Fri, October 5, 2018
Thu, October 4, 2018
Wed, October 3, 2018

David Risinger Maintained (AMRX) at Buy with Decreased Target to $24 on, Oct 3rd, 2018


Published on 2024-10-26 09:09:31 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Buy with Decreased Target from $26 to $24 on, Oct 3rd, 2018.

David has made no other calls on AMRX in the last 4 months.



There are 4 other peers that have a rating on AMRX. Out of the 4 peers that are also analyzing AMRX, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Dewey Steadman of "Canaccord Genuity" Maintained at Hold with Increased Target to $21 on, Tuesday, August 14th, 2018
  • Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $20 on, Friday, August 10th, 2018


These are the ratings of the 2 analyists that currently disagree with David


  • David Buck of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $28 on, Wednesday, August 22nd, 2018
  • Randall Stanicky of "RBC Capital" Upgraded from Hold to Buy on, Monday, August 13th, 2018